Welcome to the Agenix Limited international website.

Please select one of our company options below for more information.

Agenix Limited - Aegis Research Report - December 20, 2007

Agenix Limited was listed on the Australian Stock Exchange in October 1987. Today's two primary businesses consist of AGEN Biomedical (headquartered in Brisbane, Australia) and Agenix Bio-Pharma Shanghai, in The People's Republic of China.

For more information regarding the stock, board or investor relations, please select any of the links to the left.

The primary focus of AGEN Biomedical is the research and development of monoclonal antibody products such as our lead clinical trial agent, ThromboView®.  

For more information regarding ThromboView please click view more below.

Agenix Biopharmaceutical (Shanghai) joined the Agenix family of companies in April of 2007. YouHeDing, its anti-hepatitis B virus drug is currently being released into the Chinese market while several anti-virus, anti-cancer drugs are in development. Organizational headquarters are located in Shanghai, China.

For more information regarding Agenix Biopharmaceutical (Shanghai) please click on view more below.